Overview
The Retatrutide 40mg vial sits between Nova Biolabs' 30mg and 60mg options — for research programmes that need more material than the 30mg vial provides, without committing to the larger 60mg spend. Retatrutide's triple GLP-1/GIP/glucagon receptor mechanism remains one of the most closely studied areas in current metabolic peptide research.
Held in UK domestic stock and dispatched with fast, discreet packaging.
Key Research Areas
Multi-Arm Study Planning
The 40mg fill weight gives researchers more flexibility when splitting a single vial across several concurrent experimental arms without over-ordering.
GLP-1, GIP and Glucagon Receptor Co-Activation
Studying the simultaneous activation of all three receptors and their downstream intracellular signalling pathways remains a key focus of current metabolic research.
Hepatic Glucose Research
The glucagon receptor component of Retatrutide is particularly relevant to research examining hepatic glucose output, glycogenolysis, and gluconeogenesis signalling.
Adipose and Thermogenesis Research
Investigated in fat cell models for its interactions with adipogenesis signalling and thermogenic pathway activation.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 40mg per vial |
| Grade | Research Grade |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |
Frequently Asked Questions
Commonly Stacked With
Compounds researchers often study alongside this one, and why.
Both feature in Nova’s Premium Bundle — MOTS-c’s mitochondrial signalling research is a common pairing alongside triple-receptor agonist studies.
Paired in the Premium Bundle — NAD+’s role in cellular energy pathways is frequently studied alongside metabolic receptor agonists.
Both feature in Nova’s Elite Bundle — GHRH-analogue research is commonly combined with metabolic receptor studies for broader endocrine-axis coverage.